Animals are exposed to a wide variety of environmental stresses, and they may employ both specific and general strategies to tolerate such stresses. To identify mechanisms that permit C. elegans to tolerate high levels of dietary zinc, we screened for mutations that enhanced growth and survival in high levels of supplemental zinc. We identified a C. elegans N-terminal acetyltransferase (NAT) gene in this screen, which we named
natc-1.
natc-1 encodes a protein that is homologous to the vertebrate NAA35, an auxiliary subunit of the NatC complex. NATs function in complexes to catalyze the N-terminal acetylation of proteins, which is a widespread modification that affects the majority of eukaryotic proteins. However, relatively little is known about the biological functions of NATs. We demonstrated that mutations in
natc-1 cause resistance to a broad spectrum of physiologic stressors, including heavy metals, heat, and oxidation.
natc-1 was identified based on resistance to zinc excess, yet the stress resistance conferred by
natc-1 loss-of-function is protective against a wide range of environmental stresses. The C. elegans FOXO transcription factor DAF-16 is a key component of the insulin/IGF-1 pathway that mediates general stress resistance and has been predicted to directly bind the
natc-1 promoter. To characterize the role
natc-1 plays in insulin/IGF-1 signaling, we analyzed molecular and genetic interactions with key components of the insulin/IGF-1 pathway. We demonstrated that
natc-1 is transcriptionally repressed by DAF-16 and that mutations in
natc-1 are epistatic to
daf-16 mutations with respect to stress resistance. Furthermore,
natc-1 inhibits dauer formation in a sensitized genetic background. Based on these findings, we hypothesize that
natc-1 functions as a downstream effector of the insulin/IGF-1 signaling pathway to mediate stress resistance and dauer formation. These studies identify a novel biological function for
natc-1 as a modulator stress resistance and dauer formation and define a functionally significant downstream effector of the insulin/IGF-1 signaling pathway.